Current stock page

Financial Data

AVBP Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

AVBPArriVent BioPharma, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

BearishEdge 5/10
$13.01−$0.06 (−0.46%)

Latest quote

  • Momentum
    23
  • Value
    —
  • Quality
    51
  • Risk resilience
    32
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$5M$0$0$0$0$0$0$0
Gross Profit$5M$0$0$0$0$0$0$0
Operating Income-$43.38M-$52.69M-$46.11M-$38.82M-$38.32M-$33.62M-$66.77M-$23.71M
Net Income-$40.31M-$49.89M-$43.32M-$35.54M-$34.98M-$31.4M-$64.39M-$20.63M
EPS-$0.81-$1.05-$0.96-$0.84-$0.83-$0.9-$1.9-$0.61
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$40.71M-$39.58M-$41.89M-$30.66M-$35.8M-$26.12M-$68.01M-$16.15M
Capital Expenditure$0$0$0$0$0$0$0$0
Free Cash Flow-$40.71M-$39.58M-$41.89M-$30.66M-$35.8M-$26.12M-$68.01M-$16.15M
Net Cash Provided By Operating Activities-$40.71M-$39.58M-$41.89M-$30.66M-$35.8M-$26.12M-$68.01M-$16.15M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$417.09M$394.72M$349.3M$333.17M$326.56M$269.51M$215.5M$274.94M
Total Debt$256K$351K$419K$14K$56K$98K$138K$176K
Cash And Cash Equivalents$113.58M$154.68M$62.1M$45.54M$112.67M$112.77M$49.87M$74.29M
Total Liabilities$23.61M$27.88M$25.32M$25.95M$21.56M$19.64M$12.95M$17.29M
Total Stockholders Equity$393.48M$366.84M$323.98M$307.22M$305M$249.87M$202.54M$257.65M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio1.784.084.043.162.562.443.352.87
P/S ratio128.87———————
Debt To Equity00000000
Free Cash Flow Yield-21.79%-9.88%-10.28%-16.54%-18.74%-20.80%-17.65%-9.49%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio1.784.084.043.162.562.443.352.87
P/S ratio128.87———————
Return On Equity-42.97%-44.63%-44.83%-54.13%-49.64%-54.82%-62.93%-31.24%
Debt To Equity00000000

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-3.55x
Pb1.64x
EPS Growth Yoy2.41%
Gross Margin100.00%
Operating Margin-3620.02%
ROE-48.60%
ROIC-45.97%
Debt To Equity0
FCF Yield-22.71%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$13.01
Volume616,143
RSI (14)34.11
MACD-2.27
MACD signal-2.52
MACD histogram0.25
ADX (14)31.85
SMA (50)$21.36
SMA (200)$26.48
ATR (14)$1.47
Historical volatility (annualized)132.57%
Volume (20-day average)1.43M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score32/100
Beta1.14
Annual volatility81.51%
Max Drawdown-64.80%
Sharpe Ratio-0.08
VaR (95%, 1-day)-5.29%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

AVBP Financial Data FAQ

What is ArriVent BioPharma, Inc.'s revenue?

ArriVent BioPharma, Inc.'s revenue is one of the core financial data points for AVBP. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is ArriVent BioPharma, Inc.'s revenue growing?

Revenue growth shows whether ArriVent BioPharma, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is AVBP's EPS?

AVBP's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is ArriVent BioPharma, Inc.'s net income?

ArriVent BioPharma, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does ArriVent BioPharma, Inc. generate?

Free cash flow shows how much cash ArriVent BioPharma, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does ArriVent BioPharma, Inc. have?

Cash and debt help frame AVBP's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.